Ally Bridge Group
Global healthcare investment management firm focused on life-science innovation. Founded in 2013 with offices in New York and Hong Kong, the firm invests across private and public capital structures and combines scientific and clinical research evaluation with M&A and capital markets execution to support portfolio company development and cross-border commercialization. The firm is active in buyouts, take-private transactions and public listing advisory, including cross-border listings and relistings between the U.S., Hong Kong and mainland China.
Ally Bridge Group
Hong Kong, Hong Kong Island, Hong Kong, Asia
Services
Private equity investments
Sourcing, leading and co-leading private equity financings across medtech, biotech and healthcare services.
Public equity strategy and portfolio management
Long-biased public equity strategy focusing on healthcare and life-science companies.
Cross-border commercialization and market entry advisory
Advisory and partnership facilitation to accelerate market entry and commercialization in China, the U.S. and Europe.
Fund formation, capital raising and investor relations
Fund administration, capital formation and investor communications for fund sponsors and limited partners.
Portfolio commercialization and operational support
Support for commercial expansion, manufacturing scale-up and strategic partnerships for portfolio companies.
Public listing and relisting advisory
Advisory services for IPO execution and relisting strategies across Hong Kong, mainland China and U.S. markets.
Private equity investments
Sourcing, leading and co-leading private equity financings across medtech, biotech and healthcare services.
Public equity strategy and portfolio management
Long-biased public equity strategy focusing on healthcare and life-science companies.
Cross-border commercialization and market entry advisory
Advisory and partnership facilitation to accelerate market entry and commercialization in China, the U.S. and Europe.
Fund formation, capital raising and investor relations
Fund administration, capital formation and investor communications for fund sponsors and limited partners.
Portfolio commercialization and operational support
Support for commercial expansion, manufacturing scale-up and strategic partnerships for portfolio companies.
Public listing and relisting advisory
Advisory services for IPO execution and relisting strategies across Hong Kong, mainland China and U.S. markets.
Expertise Areas
- Healthcare investment management
- Private equity and buyout transactions
- Public equity and IPO advisory
- Cross-border market access (U.S.-China-Europe)
Key Technologies
- Next-generation sequencing (NGS) and genomics
- Single-cell and multi-omics analysis
- AI/ML-driven drug discovery
- Surgical robotics platforms